russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2024-5580USRZZVrussjcardiol-5580Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯ. ОБЗОР ЛИТЕРАТУРЫCLINIC AND PHARMACOTHERAPY. LITERATURE REVIEWАнтифибротические эффекты ингибиторов натрий-глюкозного котранспортера 2-го типа (SGLT2) у пациентов с сердечной недостаточностьюAntifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failurehttps://orcid.org/0000-0001-5194-0981ИгнатоваЮ. С.IgnatovaYu. S.

Игнатова Юлия Сергеевна — к.м.н., н.с. лаборатории фиброгенеза

Кемерово

Kemerovo

julia-smolina@mai.ruhttps://orcid.org/0009-0002-8294-1826ШустерС. Ю.ShusterS. U.

Шустер Софья Юрьевна — лаборант-исследователь лаборатории фиброгенеза

Кемерово

Kemerovo

shustermd@yandex.ruhttps://orcid.org/0000-0002-4771-484XПечеринаТ. Б.PecherinaT. B.

Печерина Тамара Борзалиевна — д.м.н., зав. лабораторией фиброгенез

Кемерово

Kemerovo

tb.pechorina@gmail.comhttps://orcid.org/0000-0002-4642-3610БарбарашО. Л.BarbarashO. L.

Барбараш Ольга Леонидовна — академик РАН, д.м.н., профессор, зав. кафедрой кардиологии и сердечно-сосудистой хирургии ФГБОУ ВО Кемеровского государственного медицинского университета Минздрава РФ, директор ФГБНУ Научно-исследовательского института комплексных проблем сердечно-сосудистых заболеваний

Кемерово

 

Kemerovo

olb61@mail.ruФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеванийРоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian FederationФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний; ФГБОУ ВО Кемеровский государственный медицинский университетРоссияResearch Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical UniversityRussian Federation20240610202329155805580Copyright © Игнатова Ю.С., Шустер С.Ю., Печерина Т.Б., Барбараш О.Л., 20242024Игнатова Ю.С., Шустер С.Ю., Печерина Т.Б., Барбараш О.Л.Ignatova Y.S., Shuster S.U., Pecherina T.B., Barbarash O.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5580

Сердечная недостаточность (СН) — актуальная проблема общественного здравоохранения во всем мире. Основополагающая роль в прогрессировании СН отводится фиброзу, вызывающему структурные изменения миокарда и сосудистой стенки. В связи с этим представляется актуальным поиск патогенетически обоснованной терапии для лечения СН, направленной на замедление прогрессирования фиброза миокарда. Результаты исследования EMPA-REG OUTCOME показали, что сахароснижающие препараты, а именно ингибиторы натрий-глюкозного котранспортера 2 типа (SGLT2) положительно влияют на течение СН, снижая сердечно-сосудистую смертность и число госпитализаций пациентов по поводу декомпенсации СН. При изучении ингибиторов SGLT2 в крупномасштабных исследованиях были выявлены антифибротические свойства этой группы препаратов. В обзорной статье представлены результаты экспериментальных исследований применения ингибиторов SGLT2 на животных. Описан ряд механизмов реализации антифибротических свойств ингибиторов SGLT2, влияющих на сердечно-сосудистую систему. Представляется актуальным дальнейшее изучение ингибиторов SGLT2 в клинических исследованиях с целью выявления и коррекции патогенетических механизмов фиброзирования миокарда.

Heart failure (HF) is an urgent public health problem worldwide. A fundamental role in HF progression is played by fibrosis, which causes structural myocardial and vascular changes. In this regard, it seems relevant to search for pathogenetically justified HF therapy, aimed at slowing the myocardial fibrosis progression. The results of EMPA-REG OUTCOME study showed that glucose-lowering drugs, namely sodium-glucose cotransporter 2 (SGLT2) inhibitors, have a positive effect on HF course, reducing cardiovascular mortality and hospitalization rate of patients for decompensated HF. Large-scale studies showed the antifibrotic properties of SGLT2 inhibitors. The review article presents the results of experimental studies on the use of SGLT2 inhibitors in animals. A number of mechanisms for the implementation of the antifibrotic properties of SGLT2 inhibitors affecting the cardiovascular system have been described. It seems relevant to further study SGLT2 inhibitors in clinical trials in order to identify and correct the pathogenetic mechanisms of myocardial fibrosis.

ингибиторы натрий-глюкозного котранспортера 2-го типасердечная недостаточностьфиброз миокардапрогноз.sodium-glucose cotransporter type 2 inhibitorsheart failuremyocardial fibrosisprognosisReferencesTheofilis P, Sagris M, Oikonomou E, et al. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Res Clin Pract. 2022;188:109927. doi:10.1016/j.diabres.2022.109927.Theofilis P, Sagris M, Oikonomou E, et al. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Res Clin Pract. 2022;188:109927. doi:10.1016/j.diabres.2022.109927.Xu GR, Zhang C, Yang HX, et al. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway. Biomed Pharmacother. 2020;126:110071. doi:10.1016/j.biopha.2020.110071.Xu GR, Zhang C, Yang HX, et al. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway. Biomed Pharmacother. 2020;126:110071. doi:10.1016/j.biopha.2020.110071.Webber M, Jackson ST, Moon JC, et al. Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials. Cardiol Ther. 2020;9(2):363-76. doi:10.1007/s40119-020-00199-y.Webber M, Jackson ST, Moon JC, et al. Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials. Cardiol Ther. 2020;9(2):363-76. doi:10.1007/s40119-020-00199-y.Moady G, Tuvia B G, Shaul A. Sodium-Glucose Co-Transporter 2 Inhibitors in Heart FailureCurrent Evidence in Special Populations. Life (Basel). 2023;13(6):1256. doi:10.3390/life13061256.Moady G, Tuvia B G, Shaul A. Sodium-Glucose Co-Transporter 2 Inhibitors in Heart FailureCurrent Evidence in Special Populations. Life (Basel). 2023;13(6):1256. doi:10.3390/life13061256.Palmiero G, Cesaro A, Vetrano E, et al. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. Int J Mol Sci. 2021;22(11):5863. doi:10.3390/ijms22115863.Palmiero G, Cesaro A, Vetrano E, et al. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. Int J Mol Sci. 2021;22(11):5863. doi:10.3390/ijms22115863.Benham JL, Booth JE, Sigal RJ, et al. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc. 2021;33:100725. doi:10.1016/j.ijcha.2021.100725.Benham JL, Booth JE, Sigal RJ, et al. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc. 2021;33:100725. doi:10.1016/j.ijcha.2021.100725.Marshall RP, Simpson JK, Lukey PT. Strategies for biomarker discovery in fibrotic disease. Biochim Biophys Acta. 2013;1832(7):1079-87. doi:10.1016/j.bbadis.2013.01.018.Marshall RP, Simpson JK, Lukey PT. Strategies for biomarker discovery in fibrotic disease. Biochim Biophys Acta. 2013;1832(7):1079-87. doi:10.1016/j.bbadis.2013.01.018.Ali O, Hajduczok AG, Boehmer JP. Remote Physiologic Monitoring for Heart Failure. Curr Cardiol Rep. 2020;22(8):68. doi:10.1007/s11886-020-01309-x.Ali O, Hajduczok AG, Boehmer JP. Remote Physiologic Monitoring for Heart Failure. Curr Cardiol Rep. 2020;22(8):68. doi:10.1007/s11886-020-01309-x.Jumppanen M, Kinnunen SM, Välimäki MJ, et al. Synthesis, Identification, and StructureActivity Relationship Analysis of GATA4 and NKX2-5 Protein-Protein Interaction Modulators. J Med Chem. 2019;62(17):8284-310. doi:10.1021/acs.jmedchem.9b01086.Jumppanen M, Kinnunen SM, Välimäki MJ, et al. Synthesis, Identification, and StructureActivity Relationship Analysis of GATA4 and NKX2-5 Protein-Protein Interaction Modulators. J Med Chem. 2019;62(17):8284-310. doi:10.1021/acs.jmedchem.9b01086.Migneault F, Hébert MJ. Autophagy, tissue repair, and fibrosis: a delicate balance. Matrix Biol. 2021;100-1:182-96. doi:10.1016/j.matbio.2021.01.003.Migneault F, Hébert MJ. Autophagy, tissue repair, and fibrosis: a delicate balance. Matrix Biol. 2021;100-1:182-96. doi:10.1016/j.matbio.2021.01.003.Ung CY, Onoufriadis A, Parsons M, et al. Metabolic perturbations in fibrosis disease. Int J Biochem Cell Biol. 2021;139:106073. doi:10.1016/j.biocel.2021.106073.Ung CY, Onoufriadis A, Parsons M, et al. Metabolic perturbations in fibrosis disease. Int J Biochem Cell Biol. 2021;139:106073. doi:10.1016/j.biocel.2021.106073.Каретникова В.Н., Кашталап В.В., Косарева С.Н. и др. Фиброз миокарда: современные аспекты проблемы. Терапевтический архив. 2017;89(1):88-93. doi:10.17116/terarkh201789188-93.Karetnikova VN, Kashtalap VV, Kosareva SN, et al. Myocardial fibrosis: current aspects of the problem. Therapeutic archive. 2017;89(1):88-93. (In Russ.) doi:10.17116/terarkh201789188-93.Ma ZG, Yuan YP, Wu HM, et al. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci. 2018;14(12):1645-57. doi:10.7150/ijbs.28103.Ma ZG, Yuan YP, Wu HM, et al. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci. 2018;14(12):1645-57. doi:10.7150/ijbs.28103.Kohl P, Camelliti P. Fibroblast-myocyte connections in the heart. Heart Rhythm. 2012;9(3):461-4. doi:10.1016/j.hrthm.2011.10.002.Kohl P, Camelliti P. Fibroblast-myocyte connections in the heart. Heart Rhythm. 2012;9(3):461-4. doi:10.1016/j.hrthm.2011.10.002.Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563-81. doi:10.1007/s00441-016-2431-9.Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563-81. doi:10.1007/s00441-016-2431-9.Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71(4):549-74. doi:10.1007/s00018-013-1349-6.Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71(4):549-74. doi:10.1007/s00018-013-1349-6.Fitchett D, Zinman B, Wanner Ch, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37(19):1526-34. doi:10.1093/eurheartj/ehv728.Fitchett D, Zinman B, Wanner Ch, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37(19):1526-34. doi:10.1093/eurheartj/ehv728.Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. doi:10.1186/s12933-019-0816-2.Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. doi:10.1186/s12933-019-0816-2.Tian J, Zhang M, Suo M, et al. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats. J Cell Mol Med. 2021;25(16):7642-59. doi:10.1111/jcmm.16601.Tian J, Zhang M, Suo M, et al. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats. J Cell Mol Med. 2021;25(16):7642-59. doi:10.1111/jcmm.16601.Zhang Y, Lin X, Chu Y, et al. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling. Cardiovasc Diabetol. 2021;20(1):121. doi:10.1186/s12933-021-01312-8.Zhang Y, Lin X, Chu Y, et al. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling. Cardiovasc Diabetol. 2021;20(1):121. doi:10.1186/s12933-021-01312-8.Lee S-G, Kim D, Lee J-J, et al. Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling. BMC Med. 2022;20(1):309. doi:10.1186/s12916-022-02485-z.Lee S-G, Kim D, Lee J-J, et al. Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling. BMC Med. 2022;20(1):309. doi:10.1186/s12916-022-02485-z.Ye Y, Bajaj M, Yang H-C, et al. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc. Drugs Ther. 2017;31(2):119-32. doi:10.1007/s10557-017-6725-2.Ye Y, Bajaj M, Yang H-C, et al. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc. Drugs Ther. 2017;31(2):119-32. doi:10.1007/s10557-017-6725-2.Kelley N, Jeltema D, Duan Y, et al. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20(13):3328. doi:10.3390/ijms20133328.Kelley N, Jeltema D, Duan Y, et al. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20(13):3328. doi:10.3390/ijms20133328.Lee T-M, Chang N-C, Lin S-Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med. 2017;104:298-310. doi:10.1016/j.freeradbiomed.2017.01.035.Lee T-M, Chang N-C, Lin S-Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med. 2017;104:298-310. doi:10.1016/j.freeradbiomed.2017.01.035.Byrne NJ, Matsumura N, Maayah ZH, et al. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. Circ Heart Fail. 2020;13(1):e006277. doi:10.1161/CIRCHEARTFAILURE.119.006277.Byrne NJ, Matsumura N, Maayah ZH, et al. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. Circ Heart Fail. 2020;13(1):e006277. doi:10.1161/CIRCHEARTFAILURE.119.006277.Lee HC, Shiou YL, Jhuo SJ, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18(1):45. doi:10.1186/s12933-019-0849-6.Lee HC, Shiou YL, Jhuo SJ, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18(1):45. doi:10.1186/s12933-019-0849-6.Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study. JACC Heart Fail. 2021;9(8):578-89. doi:10.1016/j.jchf.2021.04.014.Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study. JACC Heart Fail. 2021;9(8):578-89. doi:10.1016/j.jchf.2021.04.014.Kang S, Verma S, Hassanabad AF, et al. Direct effects of Empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: Novel translational clues to explain EMPAREG Outcome results. Can. J. Cardiol. 2020;36(4):543-53. doi:10.1016/j.cjca.2019.08.033.Kang S, Verma S, Hassanabad AF, et al. Direct effects of Empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: Novel translational clues to explain EMPAREG Outcome results. Can. J. Cardiol. 2020;36(4):543-53. doi:10.1016/j.cjca.2019.08.033.Koyani CN, Plastira I, Sourij H, et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol. Res. 2020;158:104870. doi:10.1016/j.phrs.2020.104870.Koyani CN, Plastira I, Sourij H, et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol. Res. 2020;158:104870. doi:10.1016/j.phrs.2020.104870.Hasan R, Lasker S, Hasan A, et al. Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways. Sci. Rep. 2020;10(1):14459. doi:10.1038/s41598-020-71449-1.Hasan R, Lasker S, Hasan A, et al. Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways. Sci. Rep. 2020;10(1):14459. doi:10.1038/s41598-020-71449-1.Jiang F, Liu G-S, Dusting GJ, et al. NADPH oxidase-dependent redox signaling in TGF-betamediated fibrotic responses. Redox Biol. 2014;2:267-72. doi:10.1016/j.redox.2014.01.012.Jiang F, Liu G-S, Dusting GJ, et al. NADPH oxidase-dependent redox signaling in TGF-betamediated fibrotic responses. Redox Biol. 2014;2:267-72. doi:10.1016/j.redox.2014.01.012.Pabel S, Hamdani N, Luedde M, et al. SGLT2 Inhibitors and Their Mode of Action in Heart Failure — Has the Mystery Been Unravelled? Curr Heart Fail Rep. 2021;18(5):315-28. doi:10.1007/s11897-021-00529-8.Pabel S, Hamdani N, Luedde M, et al. SGLT2 Inhibitors and Their Mode of Action in Heart Failure — Has the Mystery Been Unravelled? Curr Heart Fail Rep. 2021;18(5):315-28. doi:10.1007/s11897-021-00529-8.Сабиров И.С., Муркамилов И.Т., Фомин В.В. Кардиопротективный потенциал ингибиторов натрий-глюкозного котранспортера (фокус на Эмпаглифлозин). Комплексные проблемы сердечно-сосудистых заболеваний. 2021;10(3):79-89. doi:10.17802/2306-1278-2021-10-3-79-89.Sabirov IS, Murkamilov IT, Fomin VV. Potential mechanisms underlying cardiovascular protection by sodium glucose cotransporter 2 inhibitors (empagliflozin). Complex Issues of Cardiovascular Diseases. 2021;10(3):79-89. (In Russ.) doi:10.17802/2306-1278-2021-10-3-79-89.Baartscheer A, Schumacher CA, Van Borren MMGJ, et al. Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc. Res. 2003;57(4):1015-24. doi:10.1016/S0008-6363(02)00809-x.Baartscheer A, Schumacher CA, Van Borren MMGJ, et al. Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc. Res. 2003;57(4):1015-24. doi:10.1016/S0008-6363(02)00809-x.Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018;61(3):722-6. doi:10.1007/s00125-017-4509-7.Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018;61(3):722-6. doi:10.1007/s00125-017-4509-7.Trum M, Riechel J, Lebek S, et al. Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes. ESC Heart Fail. 2020;7(6):4429-37. doi:10.1002/ehf2.13024.Trum M, Riechel J, Lebek S, et al. Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes. ESC Heart Fail. 2020;7(6):4429-37. doi:10.1002/ehf2.13024.Cheng ST, Chen L, Li SY, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic beta-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS ONE. 2016;11(1):e0147391. doi:10.1371/journal.pone.0147391.Cheng ST, Chen L, Li SY, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic beta-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS ONE. 2016;11(1):e0147391. doi:10.1371/journal.pone.0147391.Kondo H, Akoumianakis I, Badi I, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42(48):4947-60. doi:10.1093/eurheartj/ehab420.Kondo H, Akoumianakis I, Badi I, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42(48):4947-60. doi:10.1093/eurheartj/ehab420.Bray JJ, Foster-Davies H, Stephens JW. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Res Clin Pract. 2020;168:108368. doi:10.1016/j.diabres.2020.108368.Bray JJ, Foster-Davies H, Stephens JW. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Res Clin Pract. 2020;168:108368. doi:10.1016/j.diabres.2020.108368.Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J.Pharmacol. 2013;715(1-3):246-55. doi:10.1016/j.ejphar.2013.05.014.Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J.Pharmacol. 2013;715(1-3):246-55. doi:10.1016/j.ejphar.2013.05.014.Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J. Pharm. Pharmacol. 2014;66(7):975-87. doi:10.1111/jphp.12223.Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J. Pharm. Pharmacol. 2014;66(7):975-87. doi:10.1111/jphp.12223.Garvey WT, Gaal LV, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32-7. doi:10.1016/j.metabol.2018.02.002.Garvey WT, Gaal LV, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32-7. doi:10.1016/j.metabol.2018.02.002.Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44(6):457-64. doi:10.1016/j.diabet.2018.09.005.Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44(6):457-64. doi:10.1016/j.diabet.2018.09.005.Prattichizzo F, Nigris VD, Micheloni S, et al. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component? Diabetes Obes. Metab. 2018;20(11):2515-22. doi:10.1111/dom.13488.Prattichizzo F, Nigris VD, Micheloni S, et al. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component? Diabetes Obes. Metab. 2018;20(11):2515-22. doi:10.1111/dom.13488.Kim SR, Lee S-G, Kim SH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 2020;11(1):2127. doi:10.1038/s41467-020-15983-6.Kim SR, Lee S-G, Kim SH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 2020;11(1):2127. doi:10.1038/s41467-020-15983-6.

The authors declare that there are no conflicts of interest present.